The authors Reply: Parienti suggests that drugresistant minority quasi-species present at study entry and not detected by means of consensus sequencing may have contributed to virologic failure. We agree that this is a potential explanation for the findings, and we plan to investigate baseline samples obtained from the patients with virologic failure and controls using allelespecific polymerase-chain-reaction assays 1 and pyrosequencing 2 to test this hypothesis. Since minority species are probably equally prevalent in both treatment groups because of randomization, we are particularly interested in mutations that may confer different effects on susceptibility to abacavir and tenofovir, such as a substitution of a methionine for a valine at residue 184 in HIV-1 reverse transcriptase (M184V mutation). 3 The study started before baseline genotypic resistance testing was recommended in treatment guidelines. It is not readily apparent why having baseline genotypic testing performed at the discretion of the provider was associated with a higher risk of virologic failure to abacavir-lamivudine than to tenofovir DF-emtricitabine. We speculate that physicians who chose to obtain a baseline resistance test may have done so for patients who were perceived to be at a higher risk for resistance.
We agree with Leiner that knowledge of drugresistance mutations at the time of treatment failure is the standard of care for patient treatment. That information was provided to the study participants and their primary providers as soon as the results were available to guide selection of the next regimen (see the Supplementary Appendix, available with the full text of our article at NEJM .org, for the full study protocol). The data and safety monitoring board request was that the full data on resistance not be released to the protocol team, since the study was ongoing; however, each individual provider did receive the necessary data to make an informed choice about treatment options. Paul E. Sax, M.D.
Effects of Obesity and Smoking on U.S. Life Expectancy
To the Editor: Mortality from adult obesity and from persistent smoking have already been reliably assessed in studies of tens of thousands of deaths. [1] [2] [3] [4] A common measure of obesity is the body-mass index (BMI, the weight in kilograms divided by the square of the height in meters). 2 An increase of 2 in the BMI in overweight populations and an increase of 10% in the prevalence of smoking reduce the life span in men comparably, each by about 1 year (Fig. 1) No potential conflict of interest relevant to this letter was reported.
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cause-specific mortality in 900,000 adults: collaborative analyses of 57 prospective studies. 
The authors reply:
The relative risks of all-cause mortality in our article are comparable to those from multiple U.S. studies [1] [2] [3] [4] [5] and are broadly consistent with those in the studies cited by Peto and colleagues. They note an approximate 1-year reduction in life expectancy associated with an increase of 2 in the BMI or an increase of 10% in the prevalence of smoking. Our data suggest a reduction in life expectancy of 0.66 years for the BMI increase of 2 and a reduction in life expectancy of 0.77 years for the increased prevalence of smoking of 10%. Thus, the overwhelming effect of obesity in our study was driven not by an underestimation of the hazards of tobacco use relative to those of an elevated BMI, but rather by the greater prevalence of obesity as compared with smoking in the U.S. population. This population perspective should not obscure the large gains that are possible for persons who quit smoking. 
